NSF award 2528179 · Immuno Nano MED, INC

STTR Phase I: Room Temperature Stable, Dry Powder Particle-Based Vaccines Against Influenza

Final report due

29 July 2027

in 284 days · The award ends on 31 March 2027.

GrantClerk is a private service. We are not NSF or any government agency.

Dates this award owes

NSF emails you about this too.

Decide about an extension1 Dec 2026in 44 days
award ending 2027-03-31 · Research.gov
This one is ours, not NSF’s.
Extension request14 Feb 2027in 119 days
award ending 2027-03-31 · Research.gov
PAPPG 24-1: “at least 45 days prior to the end date”
No-cost extension notice21 Mar 2027in 154 days
award ending 2027-03-31 · Research.gov
PAPPG 24-1: “at least ten calendar days prior to the end date”
Final report due29 Jul 2027in 284 days
award ending 2027-03-31 · Research.gov
PAPPG 24-1: “no later than 120-days following the end date of the award”
Project outcomes report due29 Jul 2027in 284 days
award ending 2027-03-31 · Research.gov
PAPPG 24-1: “no later than 120 days following the end date”
Award is closed out29 Jul 2027in 284 days
award ending 2027-03-31 · Research.gov
PAPPG 24-1: “financially closed out 120 days after their expiration date”

Annual report dates come from the budget period on your award notice. That date is not public, so it is not shown here.

How we got this date

NSF lists this award's end date as 31 March 2027.
NSF rules say the final report is due no later than 120 days after that.
So the final report is due by 29 July 2027.

Read the rule on Research.gov

Get a note before each report date

Add this award to your desk. We email you before each date and keep the dates in one place.

Renews each year until you cancel. Cancel any time from your account.

Already a member? Sign in

Award card

Award number: 2528179
Period of support: 1 Oct 2025 – 31 Mar 2027
Amount: $305,000
Awardee: Immuno Nano MED, INC, Ames, IA
Program: STTR Phase I
Directorate: TIP

Abstract

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is to demonstrate room-temperature-stable, dry powder inhalable influenza vaccines represent as an innovative, next generation technology to promote the health and welfare of the American public by eliminating the existing pain points of current influenza vaccines. The global influenza vaccine market size is…

Is this right?

We copy this from the public NSF award record. Your award notice and NSF always win. If a date looks wrong, check Research.gov.